Spots Global Cancer Trial Database for berzosertib

Every month we try and update this database with for berzosertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)	NCT04768296	Small-cell Lung...	Berzosertib Berzosertib Topotecan	18 Years -	EMD Serono
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors	NCT02589522	Metastatic Lung... Metastatic Lung... Metastatic Lung... Metastatic Mali... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Berzosertib Quality-of-Life... Therapeutic Con... Whole-Brain Rad...	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02595892	Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Berzosertib Gemcitabine Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer	NCT02567409	Metastatic Blad... Metastatic Rena... Metastatic Uret... Stage IV Bladde...	Berzosertib Cisplatin Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs	NCT03896503	Bladder Small C... Extensive Stage... Extrapulmonary ... Limited Stage L... Platinum-Resist... Platinum-Sensit... Prostate Small ... Recurrent Lung ...	Berzosertib Biopsy Biospecimen Col... Computed Tomogr... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02595892	Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Berzosertib Gemcitabine Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	NCT03641313	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Unresectable Ga... Unresectable Ga...	Berzosertib Computed Tomogr... Endoscopic Biop... Irinotecan Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs	NCT03896503	Bladder Small C... Extensive Stage... Extrapulmonary ... Limited Stage L... Platinum-Resist... Platinum-Sensit... Prostate Small ... Recurrent Lung ...	Berzosertib Biopsy Biospecimen Col... Computed Tomogr... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)	NCT04768296	Small-cell Lung...	Berzosertib Berzosertib Topotecan	18 Years -	EMD Serono
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)	NCT05246111	Advanced Solid ...	[14C]M6620 M6620 Topotecan	18 Years -	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors	NCT04266912	Metastatic Mali... Refractory Mali... Unresectable Ma...	Avelumab Berzosertib	18 Years -	M.D. Anderson Cancer Center
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02595931	Metastatic Colo... Metastatic Lung... Metastatic Mali... Metastatic Panc... Refractory Colo... Refractory Lung... Refractory Mali... Refractory Panc... Stage III Color... Stage III Lung ... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Pancre... Unresectable Co... Unresectable Lu... Unresectable Ma... Unresectable Pa...	Berzosertib Biopsy Specimen Biospecimen Col... Computed Tomogr... Irinotecan Hydr...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT03517969	Castration-Resi... Metastatic Pros... Stage IV Prosta...	Berzosertib Carboplatin Docetaxel Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors	NCT02589522	Metastatic Lung... Metastatic Lung... Metastatic Lung... Metastatic Mali... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Berzosertib Quality-of-Life... Therapeutic Con... Whole-Brain Rad...	18 Years -	National Cancer Institute (NCI)
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors	NCT02589522	Metastatic Lung... Metastatic Lung... Metastatic Lung... Metastatic Mali... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Berzosertib Quality-of-Life... Therapeutic Con... Whole-Brain Rad...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world:

Spots Global Cancer Trial Database for berzosertib

Every month we try and update this database with for berzosertib cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for berzosertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.